Advertisement
IMA vs SLXN
Which Stock Would AI Choose? ImageneBio (IMA) vs. Silexion Therapeutics (SLXN) Stock Comparison
Key Takeaways
- IMA (ImageneBio) holds a substantially stronger balance sheet, with roughly $136 million in cash and marketable securities and a runway into early 2028.
- SLXN (Silexion Therapeutics) is an earlier-stage oncology program that recently completed a reverse share split, a step often associated with financial repositioning.
- Both names are clinical-stage biotechs, but they target different markets: IMA focuses on autoimmune and inflammatory diseases, while SLXN develops RNAi therapies for KRAS-driven cancers.
- Tickeron AI Verdict: IMA currently presents the more favorable risk-reward profile based on stronger cash reserves, clearer catalysts, and more stable market positioning.
- For additional context, you can review IMA Major News and IMA Today's Price Move, as well as SLXN Major News and SLXN Today's Price Move.
- To explore AI-driven trading strategies across both tickers, visit the Trending AI Robots page.
Introduction
Investors evaluating speculative biotech opportunities frequently compare companies at different stages of clinical and financial maturity. IMA (ImageneBio, Inc.) and SLXN (Silexion Therapeutics Corp) both operate in the high-risk, high-reward world of drug development, yet they pursue very different diseases and carry very different balance-sheet profiles. This stock comparison is relevant for traders and long-term investors seeking to understand relative performance, market positioning, and risk factors across two small-cap names in the current market environment. By examining recent developments, momentum, and structural factors side by side, readers can better assess which company currently demonstrates a more favorable setup.
IMA Overview and Recent Performance
IMA, formerly Ikena Oncology, is a clinical-stage biopharmaceutical company focused on immunological, autoimmune, and inflammatory diseases. Its lead candidate, olevaprubart (formerly IMG-007), is a non-T-cell-depleting anti-OX40 monoclonal antibody being studied in a Phase 2b trial for moderate-to-severe atopic dermatitis, with a Phase 2 program in alopecia areata expected to initiate in 2026.
In recent weeks, sentiment has been shaped by steady clinical execution and capital-raising activity. The company completed a $30 million private placement in April 2026 and reported roughly $136.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, with a stated runway into the first quarter of 2028. Management has guided to topline data from the ADAPTIVE trial in the fourth quarter of 2027, giving investors a defined, if distant, catalyst. An Independent Data Monitoring Committee (IDMC) recommendation to continue the study without changes in July 2026 provided a modest reassurance on the program's progress.
SLXN Overview and Recent Performance
SLXN (Silexion Therapeutics Corp) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, a therapeutically competitive area of oncology. The company's ordinary shares and warrants trade on the Nasdaq Global Market under the symbols SLXN and SLXNW, respectively.
Recent market activity has been defined by capital-structure moves rather than clinical catalysts. The company completed a reverse share split in late May 2026, a maneuver often used to support share-price compliance and attract a broader investor base. Financially, Silexion has reported significant operating losses—$16.5 million for 2024 and $5.1 million for 2023—consistent with a pre-revenue, development-stage profile. As an earlier-stage oncology company with fewer near-term data readouts and a leaner cash position, SLXN has exhibited higher volatility and greater sensitivity to financing conditions than more advanced peers.
Trending AI Robots
For investors who prefer a systematic approach to evaluating names like IMA and SLXN, Tickeron maintains a curated Trending AI Robots section. Tickeron's platform features hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and watchlist of securities. Only the bots best suited to current market conditions earn a place in this curated selection, helping users filter a broad universe down to the most relevant strategies. Whether you are evaluating relative momentum, trend consistency, or volatility-based setups, exploring the Trending AI Robots page can add a data-driven layer to your own research process.
Head-to-Head Comparison
The two companies diverge sharply on balance-sheet strength. IMA holds a cash position sufficient to fund operations into early 2028, while SLXN operates with a materially leaner runway typical of an earlier-stage oncology developer. This translates into differing risk profiles: IMA can reach its Phase 2b data readout without near-term dilution pressure, whereas SLXN may remain more dependent on future financing events.
On growth drivers, IMA benefits from a diversified, "pipeline-in-a-product" thesis spanning atopic dermatitis and alopecia areata, backed by proof-of-concept data. SLXN is concentrated in KRAS-driven oncology, a scientifically promising but crowded field where clinical validation is still early. Sector exposure also differs: dermatology and immunology versus oncology. In terms of momentum and sentiment, IMA has shown more stable positioning around defined catalysts, while SLXN has been more reactive to structural events such as its recent reverse split.
Tickeron AI Verdict
Based on observable factors—trend consistency, financial stability, the clarity of upcoming catalysts, and relative market positioning—Tickeron's AI would currently favor IMA over SLXN. The stronger cash position, an active Phase 2b program with a defined data timeline, and a less distressed capital structure give IMA a more balanced risk-reward profile in the present environment. This assessment reflects current observable conditions rather than a definitive prediction, and relative positioning can shift as new clinical, financial, or market developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMA is a Buy and SLXN is a Hold.
IMA in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 10, 2026
IMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 42 cases where IMA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMA's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for IMA just turned positive on October 23, 2026. Looking at past instances where IMA's MACD turned positive, the stock continued to rise in 38 of 50 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMA advanced for three days, in 172 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMA as a result. In 89 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMA entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.331) is normal, around the industry mean (3.498). P/E Ratio (-0.876) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.971) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. IMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SLXN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 09, 2026
SLXN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 33 cases where SLXN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLXN advanced for three days, in 58 of 98 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLXN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SLXN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.804) is normal, around the industry mean (3.498). P/E Ratio (-0.007) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SLXN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLXN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| IMA | SLXN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 78% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 80% | N/A |
| MACD ODDS (%) | 2 days ago 76% | N/A |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 81% |
| Advances ODDS (%) | 15 days ago 79% | 8 days ago 59% |
| Declines ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMA’s FA Score shows that 1 FA rating(s) are green while SLXN’s FA Score has 0 green FA rating(s).
- IMA’s FA Score: 1 green, 4 red.
- SLXN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMA’s TA Score shows that 5 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).
- IMA’s TA Score: 5 bullish, 3 bearish.
- SLXN’s TA Score: 4 bullish, 2 bearish.
Price Growth
IMA (@Biotechnology) experienced а -5.22% price change this week, while SLXN (@Biotechnology) price change was -27.92% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
IMA is expected to report earnings on Mar 09, 2027.
SLXN is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMA has been closely correlated with CELC. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if IMA jumps, then CELC could also see price increases.
| Ticker / NAME | Correlation To IMA | 1D Price Change % | ||
|---|---|---|---|---|
| IMA | 100% | -4.03% | ||
| CELC - IMA | 77% Closely correlated | -4.72% | ||
| SLXN - IMA | 62% Loosely correlated | -11.22% | ||
| SYRE - IMA | 33% Loosely correlated | -4.15% | ||
| RAPP - IMA | 31% Poorly correlated | -0.42% | ||
| RVMD - IMA | 31% Poorly correlated | -3.54% | ||
More | ||||
SLXN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SLXN has been loosely correlated with IMA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SLXN jumps, then IMA could also see price increases.
| Ticker / NAME | Correlation To SLXN | 1D Price Change % | ||
|---|---|---|---|---|
| SLXN | 100% | -11.22% | ||
| IMA - SLXN | 62% Loosely correlated | -4.03% | ||
| CELC - SLXN | 50% Loosely correlated | -4.72% | ||
| CDT - SLXN | 44% Loosely correlated | -33.19% | ||
| INKT - SLXN | 36% Loosely correlated | -1.38% | ||
| HYFT - SLXN | 34% Loosely correlated | -4.63% | ||
More | ||||